SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi programmes utilising SanegeneBio’s technology platform.Read More